Q-omics provides the consensus-scored AKT3 profile across patient tissues and cancer cell-line models. AKT3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKT3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, AKT3 protein abundance shows 26,424 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, HNSC, and UCEC as cancer lineages where AKT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKT3 survival associations across molecular data types. AKT3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKT3 RNA expression–survival associations across cancer types. High AKT3 expression shows unfavorable associations in BLCA and STAD, but favorable associations in KIRC, HNSC, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKT3 RNA expression.
This table summarizes AKT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AKT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKT3 shows lower tumor expression in BLCA, UCEC, LUAD, KICH and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher AKT3 RNA expression in tumor versus normal tissue (log2 FC = +1.473, t-test p < 0.001).
This table shows molecular features associated with AKT3 in patient tissues and cancer cell lines. In patient samples, AKT3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
